230 related articles for article (PubMed ID: 14613029)
1. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
de Bono JS; Tolcher AW; Rowinsky EK
Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
[TBL] [Abstract][Full Text] [Related]
2. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
3. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
6. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
Zhang M; Jiang D
Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
[TBL] [Abstract][Full Text] [Related]
7. Current status of clinical trials of farnesyltransferase inhibitors.
Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors.
Hahn SM; Bernhard E; McKenna WG
Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Ras signaling in the therapy of breast cancer.
Li T; Sparano JA
Clin Breast Cancer; 2003 Feb; 3(6):405-16; discussion 417-20. PubMed ID: 12636885
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors in breast cancer therapy.
Dy GK; Adjei AA
Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Dempke WC
Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
[TBL] [Abstract][Full Text] [Related]
13. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Thomas X; Elhamri M
Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
15. Farnesyl transferase inhibitors as anticancer agents.
Haluska P; Dy GK; Adjei AA
Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
[TBL] [Abstract][Full Text] [Related]
16. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
17. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
18. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Helbig G; HoĊowiecki J
Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl transferase inhibitors in clinical development.
Caponigro F; Casale M; Bryce J
Expert Opin Investig Drugs; 2003 Jun; 12(6):943-54. PubMed ID: 12783599
[TBL] [Abstract][Full Text] [Related]
20. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Caraglia M; Budillon A; Tagliaferri P; Marra M; Abbruzzese A; Caponigro F
Curr Drug Targets; 2005 May; 6(3):301-23. PubMed ID: 15857290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
